Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Pembrolizumab for Metastatic SCLC

Jun 18, 2019, 11:31 AM
URL:
On June 17, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda, Merck) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.

Read FDA announcement.

Posted 6/18/2019

Leave a comment